These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12468829)

  • 41. Response to etanercept in juvenile idiopathic arthritis.
    Pang H; Wu XH; Xu JZ
    JAMA; 2012 Mar; 307(11):1140; author reply 1140-1. PubMed ID: 22436950
    [No Abstract]   [Full Text] [Related]  

  • 42. [Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].
    Sauvain MJ; Schalm SB; Bérthet G; Bolz D; Cannizzaro E; Hofer M; Kaiser D; Saurenmann RK; Bolt IB
    Praxis (Bern 1994); 2010 May; 99(11):649-54. PubMed ID: 20506089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
    Katsicas MM; Russo RA
    Clin Exp Rheumatol; 2005; 23(4):545-8. PubMed ID: 16095128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Etanercept in methotrexate-resistant JIA-related uveitis.
    Saeed MU; Raza SH; Goyal S; Cleary G; Newman WD; Chandna A
    Semin Ophthalmol; 2014 Jan; 29(1):1-3. PubMed ID: 24175644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Onset of multiple sclerosis associated with anti-TNF therapy.
    Sicotte NL; Voskuhl RR
    Neurology; 2001 Nov; 57(10):1885-8. PubMed ID: 11723281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
    Onishi S; Yoshio T; Nagashima T; Minota S
    Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
    [No Abstract]   [Full Text] [Related]  

  • 51. [Remarkable improvement of the hip joint lesion in a patient with rheumatoid arthritis by the treatment with anti-TNF-α agents].
    Nagare Y; Kinoshita K; Nishisaka F; Saito M; Nonaka T; Funauchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(5):272-6. PubMed ID: 21048388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

  • 53. Digital vasculitis with eosinophilia possibly associated with etanercept therapy.
    Nakahigashi K; Egawa G; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2014 Mar; 94(2):239-40. PubMed ID: 23824408
    [No Abstract]   [Full Text] [Related]  

  • 54. Etanercept improves rheumatoid arthritis partially responsive to methotrexate.
    Cutolo M
    Clin Exp Rheumatol; 2001; 19(6):626-7. PubMed ID: 11791631
    [No Abstract]   [Full Text] [Related]  

  • 55. Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?
    Berard RA; Laxer RM
    J Rheumatol; 2014 Dec; 41(12):2343-6. PubMed ID: 25452178
    [No Abstract]   [Full Text] [Related]  

  • 56. [Application of etanercept in treatment of juvenile idiopathic arthritis and adult onset still disease].
    Lewicki M; Kotulska A; Kucharz EJ
    Pol Arch Med Wewn; 2005 May; 113(5):505-8. PubMed ID: 16479836
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
    Cummins C; Connock M; Fry-Smith A; Burls A
    Health Technol Assess; 2002; 6(17):1-43. PubMed ID: 12234456
    [No Abstract]   [Full Text] [Related]  

  • 59. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS
    N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.